---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-112034"
form_type: "8-K"
ticker: "KNSA"
cik: "0001730430"
company_name: "Kiniksa Pharmaceuticals International, plc"
filed_at: "2024-10-29T23:59:59+00:00"
generated_at: "2026-05-30T09:20:07.550254+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kiniksa Q3 ARCALYST revenue $112.2M (+73% YoY); FY guidance raised to $410-420M

## Summary
- ARCALYST Q3 net product revenue $112.2M, up 73% YoY; FY 2024 guidance raised to $410-420M from $405-415M.
- Net loss narrowed to $12.7M from $13.9M; cash $223.8M, no debt.
- Over 2,550 prescribers since launch; average therapy duration ~27 months.
- Phase 2b trial of abiprubart in Sjögren's Disease enrolling/dosing; expects annual cash flow positivity.
- Launched Life DisRPted campaign with Henrik Lundqvist and Carly Pearce.

## SEC filing metadata
- accession: 0001104659-24-112034
- form_type: 8-K
- ticker: KNSA
- cik: 0001730430
- company_name: Kiniksa Pharmaceuticals International, plc
- filed_at: 2024-10-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730430/000110465924112034/0001104659-24-112034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730430/000110465924112034/tm2426983d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-112034
- JSON: https://secwatch.observer/filing/0001104659-24-112034.json
- Plain text: https://secwatch.observer/filing/0001104659-24-112034.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.